TATVA CHINTAN Q2 FY27 ; RECORD QUARTERLY REVENUE, MANAGEMENT EXPECTS EBITDA MARGIN RECOVERY

• RECORD REVENUE: Company achieved its highest-ever quarterly turnover, supported by stronger demand and commercial traction. • EBITDA PRESSURE: Despite record revenue, EBITDA remained nearly flat due to higher raw material and freight costs. • RAW MATERIAL COSTS: Certain solvents witnessed price increases of 60–100%, impacting margins. • FREIGHT COSTS: Shipping costs increased by over 100% in certain US and European sectors. • COST EFFICIENCY: Employee costs declined 2%, while other expenses decreased 2%, supporting operating leverage. • Q3 OUTLOOK: Management expects raw material and freight costs to gradually normalise during Q3 FY27. • GROWTH GUIDANCE: Expects revenue growth momentum to continue over the coming quarters, with EBITDA margins returning to a healthier trajectory. • NEW GROWTH DRIVERS: Energy storage, agrochemical and pharmaceutical intermediates are creating additional growth opportunities. • PHASE TRANSFER CATALYSTS: Management expects sustained organic growth from demand for improved manufacturing efficiency and sustainable production processes.

TATVA CHIN PHARM CHEM LTD

← Back to feed